Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Genprex Inc
(NQ:
GNPX
)
2.210
+0.090 (+4.25%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Genprex Inc
< Previous
1
2
3
4
Next >
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy
April 02, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
March 25, 2024
Via
Investor Brand Network
Exposures
Product Safety
TechMediaBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
March 25, 2024
Via
Investor Brand Network
Exposures
Product Safety
TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
March 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
March 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio
March 13, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting
March 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
February 07, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
February 07, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference
February 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
February 05, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
February 05, 2024
Via
Investor Brand Network
Exposures
Product Safety
Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer
November 22, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023
November 01, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event
October 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference
October 04, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
September 21, 2023
From
Genprex, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program
September 20, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
Via
Investor Brand Network
Exposures
Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations
September 15, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference
September 07, 2023
Via
Investor Brand Network
Exposures
Product Safety
Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline
September 05, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’
September 01, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial
August 30, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Important Clinical Programs Forward
August 22, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(R) for Patients with SCLC
August 10, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
August 04, 2023
Via
Investor Brand Network
Exposures
Product Safety
Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent
July 28, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct Offering
July 24, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.